Kazia Therapeutics Limited (KZIA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Sydney, NSW, 澳大利亚. 现任CEO为 John Edwin Friend.
KZIA 拥有 IPO日期为 1999-01-06, 9 名全职员工, 在 NASDAQ Capital Marke, 市值为 $16.2M.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
